Peptinov and the EIC Accelerator: An Arthritis Vaccine on Hold

Peptinov, a Paris biotech founded in 2009 and based at the Cochin Hospital incubator, develops PPV-06, an active immunotherapy that works like a vaccine: it makes patients produce their own antibodies against interleukin-6 (IL-6), an inflammatory protein, to slow or stop inflammatory knee osteoarthritis. It was selected in the EIC Accelerator's June 2023 cut-off with blended finance and received an EU grant of €2.50 million for Anti-IL-6, a €3.97 million project from March 2024 to February 2026 aimed at "demonstrating a clinical proof of concept" in a Phase 2 trial, according to CORDIS. The award was described as €8 million of new financing, "2,5 M€ de subvention et 5,5 M€ de capital", according to FranceTransactions, which said the trials would start in the second half of 2024.

The first report, to February 2025, says Peptinov filed its trial application in five countries in August 2024, answered 77 questions from regulators, won conditional approval in December 2024 and produced its clinical batch, according to the CORDIS reporting page. The EU trial register records authorisation decisions in France, Denmark, Czechia, Poland and Romania between 2 and 9 December 2024 for a 204-patient study, according to the EU Clinical Trials Information System. ClinicalTrials.gov lists the trial as "not yet recruiting", with an estimated start of December 2025, in an entry last updated in August 2025, according to ClinicalTrials.gov. In December 2025 Peptinov said the Phase 2 programme was "planned for 2026".

Where Peptinov Stands Now

In December 2025 Peptinov published its Phase 1 results in Nature Communications: in 24 patients the treatment was well tolerated with no serious adverse events, all treated patients developed anti-IL-6 antibodies, and function scores showed "encouraging trends", according to PR Newswire. It said it was preparing a Phase 2 programme for 2026 in knee osteoarthritis, endometriosis and rare inflammatory diseases such as giant cell arteritis and Behçet's disease. No trial start has been announced since. Its accounts are filed with a confidentiality declaration, and the French company register shows no capital increase after May 2023, according to BODACC.

The Technology: Teaching the Body to Curb Inflammation

Osteoarthritis affects more than 300 million people and has no disease-modifying treatment; current drugs only relieve pain. Peptinov's approach injects a patented piece of IL-6 linked to a carrier protein, so that the immune system treats it as foreign and makes its own antibodies against excess IL-6. The Phase 2 trial is designed to measure pain at one year and cartilage thickness by MRI at two years.

What the EIC Award Promised, and What the Record Shows

The award promised a Phase 2 proof of concept, to be used to license the drug to a large pharmaceutical company. Peptinov completed the regulatory work and trial preparation within the project, but the trial itself did not start, and the equity part of the blended award, which was to fund it, had not closed at the halfway point. There is no final report.

1. Trial authorisationDeliveredFive countries, Dec 2024.
2. Clinical batch and sitesDeliveredPer first report.
3. Phase 2 recruitmentNot startedNot yet recruiting.
4. Clinical proof of conceptNot deliveredNo trial data.

The Money

The EU grant covered 63% of the project. Peptinov raised €4.67 million from its existing shareholders in March 2023. Whether the €5.5 million of EIC equity was invested is not public, and no capital increase has been registered since 2023. A two-year, 204-patient trial in five countries needs far more money than the grant provided.

What Cannot Be Checked

Why Europe Should Care

Osteoarthritis is one of the largest causes of disability in ageing Europe, and a treatment that slows it would be worth billions to health systems. Peptinov's Phase 1 data support its approach. But the EIC paid for a trial that has not begun, and the money needed to run it has not appeared in the public record.

The Verdict

Peptinov and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.